APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Transdermal Drug Delivery System

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

Selected research

Market Outlook & Growth Opportunities

Global Transdermal Drug Delivery System Market Outlook and Growth Opportunities 2026

Report ID 17389565049 January 2026204 pages

Choose your research edition.

Industry ResearchTransdermal Drug Delivery System Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Transdermal Drug Delivery System Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Transdermal Drug Delivery System Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transdermal Drug Delivery System Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Transdermal Drug Delivery System Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.

In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.

Read the full market overview

This report provides an overview of the global Transdermal Drug Delivery System market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transdermal Drug Delivery System and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transdermal Drug Delivery System revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Transdermal Drug Delivery System market.

Transdermal Drug Delivery System Segment by Company

Hisamitsu

Mylan

GSK

Novartis

Teve (Actavis)

Johnson & Johnson

Lohmann

Teikoku Seiyaku

Bayer

Lingrui

Sanofi

Qizheng

Endo

Huarun 999

Haw Par

Nichiban

Mentholatum

Laboratoires Genevrier

Transdermal Drug Delivery System Segment by Type

Fentanyl

Nitroglycerin

Estradiol

Nicotine

Other

Transdermal Drug Delivery System Segment by Application

OTC

Rx

Transdermal Drug Delivery System Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Transdermal Drug Delivery System status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Transdermal Drug Delivery System key companies, revenue, market share, and recent developments.

3. To split the Transdermal Drug Delivery System breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Transdermal Drug Delivery System market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transdermal Drug Delivery System significant trends, drivers, influence factors in global and regions.

6. To analyze Transdermal Drug Delivery System competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug Delivery System market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug Delivery System and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug Delivery System.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transdermal Drug Delivery System industry.

Chapter 3: Detailed analysis of Transdermal Drug Delivery System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Transdermal Drug Delivery System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Transdermal Drug Delivery System in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transdermal Drug Delivery System Industry Trends Table 2. Transdermal Drug Delivery System Industry Drivers Table 3. Transdermal Drug Delivery System Industry Opportunities and Challenges Table 4. Transdermal Drug Delivery System Industry Restraints Table 5. Global Transdermal Drug Delivery System Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transdermal Drug Delivery System Revenue Share by Company (2021-2026) Table 7. Global Transdermal Drug Delivery System Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Transdermal Drug Delivery System Key Company Manufacturing Base & Headquarters Table 9. Global Transdermal Drug Delivery System Company, Product Type & Application Table 10. Global Transdermal Drug Delivery System Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Transdermal Drug Delivery System by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Fentanyl Table 15. Significant Companies of Nitroglycerin Table 16. Significant Companies of Estradiol Table 17. Significant Companies of Nicotine Table 18. Significant Companies of Other Table 19. Global Transdermal Drug Delivery System Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Transdermal Drug Delivery System Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Transdermal Drug Delivery System Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Transdermal Drug Delivery System Sales Value Share by Type (2021-2026) Table 23. Global Transdermal Drug Delivery System Sales Value Share by Type (2027-2032) Table 24. Significant Companies of OTC Table 25. Significant Companies of Rx Table 26. Global Transdermal Drug Delivery System Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Transdermal Drug Delivery System Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Transdermal Drug Delivery System Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Transdermal Drug Delivery System Sales Value Share by Application (2021-2026) Table 30. Global Transdermal Drug Delivery System Sales Value Share by Application (2027-2032) Table 31. Global Transdermal Drug Delivery System Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Transdermal Drug Delivery System Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Transdermal Drug Delivery System Sales Value Share by Region (2021-2026) Table 34. Global Transdermal Drug Delivery System Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Transdermal Drug Delivery System Sales Value Share by Region (2027-2032) Table 36. Global Transdermal Drug Delivery System Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Transdermal Drug Delivery System Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Transdermal Drug Delivery System Sales Value Market Share by Country (2021-2026) Table 39. Global Transdermal Drug Delivery System Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Transdermal Drug Delivery System Sales Value Market Share by Country (2027-2032) Table 41. Hisamitsu Company Information Table 42. Hisamitsu Business Overview Table 43. Hisamitsu Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Hisamitsu Transdermal Drug Delivery System Product Portfolio Table 45. Hisamitsu Recent Development Table 46. Mylan Company Information Table 47. Mylan Business Overview Table 48. Mylan Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Mylan Transdermal Drug Delivery System Product Portfolio Table 50. Mylan Recent Development Table 51. GSK Company Information Table 52. GSK Business Overview Table 53. GSK Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. GSK Transdermal Drug Delivery System Product Portfolio Table 55. GSK Recent Development Table 56. Novartis Company Information Table 57. Novartis Business Overview Table 58. Novartis Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Novartis Transdermal Drug Delivery System Product Portfolio Table 60. Novartis Recent Development Table 61. Teve (Actavis) Company Information Table 62. Teve (Actavis) Business Overview Table 63. Teve (Actavis) Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Teve (Actavis) Transdermal Drug Delivery System Product Portfolio Table 65. Teve (Actavis) Recent Development Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Johnson & Johnson Transdermal Drug Delivery System Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. Lohmann Company Information Table 72. Lohmann Business Overview Table 73. Lohmann Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Lohmann Transdermal Drug Delivery System Product Portfolio Table 75. Lohmann Recent Development Table 76. Teikoku Seiyaku Company Information Table 77. Teikoku Seiyaku Business Overview Table 78. Teikoku Seiyaku Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Teikoku Seiyaku Transdermal Drug Delivery System Product Portfolio Table 80. Teikoku Seiyaku Recent Development Table 81. Bayer Company Information Table 82. Bayer Business Overview Table 83. Bayer Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Bayer Transdermal Drug Delivery System Product Portfolio Table 85. Bayer Recent Development Table 86. Lingrui Company Information Table 87. Lingrui Business Overview Table 88. Lingrui Transdermal Drug Delivery System Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Lingrui Transdermal Drug Delivery System Product Portfolio Table 90. Lingrui Recent Development Table 91. Sanofi Company Information Table 92. Sanofi Business Overview Table 93. Sanofi Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Sanofi Transdermal Drug Delivery System Product Portfolio Table 95. Sanofi Recent Development Table 96. Qizheng Company Information Table 97. Qizheng Business Overview Table 98. Qizheng Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Qizheng Transdermal Drug Delivery System Product Portfolio Table 100. Qizheng Recent Development Table 101. Endo Company Information Table 102. Endo Business Overview Table 103. Endo Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Endo Transdermal Drug Delivery System Product Portfolio Table 105. Endo Recent Development Table 106. Huarun 999 Company Information Table 107. Huarun 999 Business Overview Table 108. Huarun 999 Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Huarun 999 Transdermal Drug Delivery System Product Portfolio Table 110. Huarun 999 Recent Development Table 111. Haw Par Company Information Table 112. Haw Par Business Overview Table 113. Haw Par Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Haw Par Transdermal Drug Delivery System Product Portfolio Table 115. Haw Par Recent Development Table 116. Nichiban Company Information Table 117. Nichiban Business Overview Table 118. Nichiban Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. Nichiban Transdermal Drug Delivery System Product Portfolio Table 120. Nichiban Recent Development Table 121. Mentholatum Company Information Table 122. Mentholatum Business Overview Table 123. Mentholatum Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. Mentholatum Transdermal Drug Delivery System Product Portfolio Table 125. Mentholatum Recent Development Table 126. Laboratoires Genevrier Company Information Table 127. Laboratoires Genevrier Business Overview Table 128. Laboratoires Genevrier Transdermal Drug Delivery System Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 129. Laboratoires Genevrier Transdermal Drug Delivery System Product Portfolio Table 130. Laboratoires Genevrier Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Transdermal Drug Delivery System Product Image Figure 2. Global Transdermal Drug Delivery System Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transdermal Drug Delivery System Market Size (2021-2032) & (US$ Million) Figure 4. Global Transdermal Drug Delivery System Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Fentanyl Image Figure 8. Nitroglycerin Image Figure 9. Estradiol Image Figure 10. Nicotine Image Figure 11. Other Image Figure 12. Global Transdermal Drug Delivery System Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Transdermal Drug Delivery System Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Transdermal Drug Delivery System Sales Value Share by Type (2021-2032) Figure 15. OTC Image Figure 16. Rx Image Figure 17. Global Transdermal Drug Delivery System Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Transdermal Drug Delivery System Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Transdermal Drug Delivery System Sales Value Share by Application (2021-2032) Figure 20. Global Transdermal Drug Delivery System Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Transdermal Drug Delivery System Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Transdermal Drug Delivery System Sales Value (2021-2032) & (US$ Million) Figure 23. North America Transdermal Drug Delivery System Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Transdermal Drug Delivery System Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Transdermal Drug Delivery System Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Transdermal Drug Delivery System Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Transdermal Drug Delivery System Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Transdermal Drug Delivery System Sales Value (2021-2032) & (US$ Million) Figure 29. South America Transdermal Drug Delivery System Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Transdermal Drug Delivery System Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Transdermal Drug Delivery System Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Fentanyl
  • Nitroglycerin
  • Estradiol
  • Nicotine
  • Other
Applications
  • OTC
  • Rx
Companies covered
  • Hisamitsu
  • Mylan
  • GSK
  • Novartis
  • Teve (Actavis)
  • Johnson & Johnson
  • Lohmann
  • Teikoku Seiyaku
  • Bayer
  • Lingrui
  • Sanofi
  • Qizheng
  • Endo
  • Huarun 999
  • Haw Par
  • Nichiban
  • Mentholatum
  • Laboratoires Genevrier

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Transdermal Drug Delivery System Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Transdermal Drug Delivery System Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Transdermal Drug Delivery System Market Dynamics
  1. 2.1 Transdermal Drug Delivery System Industry Trends
  2. 2.2 Transdermal Drug Delivery System Industry Drivers
  3. 2.3 Transdermal Drug Delivery System Industry Opportunities and Challenges
  4. 2.4 Transdermal Drug Delivery System Industry Restraints
3 Transdermal Drug Delivery System Market by Company
  1. 3.1 Global Transdermal Drug Delivery System Company Revenue Ranking in 2025
  2. 3.2 Global Transdermal Drug Delivery System Revenue by Company (2021-2026)
  3. 3.3 Global Transdermal Drug Delivery System Company Ranking (2024-2026)
  4. 3.4 Global Transdermal Drug Delivery System Company Manufacturing Base and Headquarters
  5. 3.5 Global Transdermal Drug Delivery System Company Product Type and Application
  6. 3.6 Global Transdermal Drug Delivery System Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Transdermal Drug Delivery System Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Transdermal Drug Delivery System Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Transdermal Drug Delivery System Market by Type
  1. 4.1 Transdermal Drug Delivery System Type Introduction
  2. 4.1.1 Fentanyl
  3. 4.1.2 Nitroglycerin
  4. 4.1.3 Estradiol
  5. 4.1.4 Nicotine
  6. 4.1.5 Other
  7. 4.2 Global Transdermal Drug Delivery System Sales Value by Type
  8. 4.2.1 Global Transdermal Drug Delivery System Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Transdermal Drug Delivery System Sales Value by Type (2021-2032)
  10. 4.2.3 Global Transdermal Drug Delivery System Sales Value Share by Type (2021-2032)
5 Transdermal Drug Delivery System Market by Application
  1. 5.1 Transdermal Drug Delivery System Application Introduction
  2. 5.1.1 OTC
  3. 5.1.2 Rx
  4. 5.2 Global Transdermal Drug Delivery System Sales Value by Application
  5. 5.2.1 Global Transdermal Drug Delivery System Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Transdermal Drug Delivery System Sales Value by Application (2021-2032)
  7. 5.2.3 Global Transdermal Drug Delivery System Sales Value Share by Application (2021-2032)
6 Transdermal Drug Delivery System Regional Value Analysis
  1. 6.1 Global Transdermal Drug Delivery System Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transdermal Drug Delivery System Sales Value by Region (2021-2032)
  3. 6.2.1 Global Transdermal Drug Delivery System Sales Value by Region: 2021-2026
  4. 6.2.2 Global Transdermal Drug Delivery System Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Transdermal Drug Delivery System Sales Value (2021-2032)
  7. 6.3.2 North America Transdermal Drug Delivery System Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Transdermal Drug Delivery System Sales Value (2021-2032)
  10. 6.4.2 Europe Transdermal Drug Delivery System Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Transdermal Drug Delivery System Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Transdermal Drug Delivery System Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Transdermal Drug Delivery System Sales Value (2021-2032)
  16. 6.6.2 South America Transdermal Drug Delivery System Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Transdermal Drug Delivery System Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Transdermal Drug Delivery System Sales Value Share by Country, 2025 VS 2032
7 Transdermal Drug Delivery System Country-level Value Analysis
  1. 7.1 Global Transdermal Drug Delivery System Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transdermal Drug Delivery System Sales Value by Country (2021-2032)
  3. 7.2.1 Global Transdermal Drug Delivery System Sales Value by Country (2021-2026)
  4. 7.2.2 Global Transdermal Drug Delivery System Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Transdermal Drug Delivery System Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Transdermal Drug Delivery System Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Transdermal Drug Delivery System Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Hisamitsu
  2. 8.1.1 Hisamitsu Company Information
  3. 8.1.2 Hisamitsu Business Overview
  4. 8.1.3 Hisamitsu Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Hisamitsu Transdermal Drug Delivery System Product Portfolio
  6. 8.1.5 Hisamitsu Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Transdermal Drug Delivery System Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Transdermal Drug Delivery System Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Transdermal Drug Delivery System Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Teve (Actavis)
  26. 8.5.1 Teve (Actavis) Company Information
  27. 8.5.2 Teve (Actavis) Business Overview
  28. 8.5.3 Teve (Actavis) Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Teve (Actavis) Transdermal Drug Delivery System Product Portfolio
  30. 8.5.5 Teve (Actavis) Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Transdermal Drug Delivery System Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Lohmann
  38. 8.7.1 Lohmann Company Information
  39. 8.7.2 Lohmann Business Overview
  40. 8.7.3 Lohmann Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lohmann Transdermal Drug Delivery System Product Portfolio
  42. 8.7.5 Lohmann Recent Developments
  43. 8.8 Teikoku Seiyaku
  44. 8.8.1 Teikoku Seiyaku Company Information
  45. 8.8.2 Teikoku Seiyaku Business Overview
  46. 8.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teikoku Seiyaku Transdermal Drug Delivery System Product Portfolio
  48. 8.8.5 Teikoku Seiyaku Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Transdermal Drug Delivery System Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Lingrui
  56. 8.10.1 Lingrui Company Information
  57. 8.10.2 Lingrui Business Overview
  58. 8.10.3 Lingrui Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lingrui Transdermal Drug Delivery System Product Portfolio
  60. 8.10.5 Lingrui Recent Developments
  61. 8.11 Sanofi
  62. 8.11.1 Sanofi Company Information
  63. 8.11.2 Sanofi Business Overview
  64. 8.11.3 Sanofi Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Transdermal Drug Delivery System Product Portfolio
  66. 8.11.5 Sanofi Recent Developments
  67. 8.12 Qizheng
  68. 8.12.1 Qizheng Company Information
  69. 8.12.2 Qizheng Business Overview
  70. 8.12.3 Qizheng Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Qizheng Transdermal Drug Delivery System Product Portfolio
  72. 8.12.5 Qizheng Recent Developments
  73. 8.13 Endo
  74. 8.13.1 Endo Company Information
  75. 8.13.2 Endo Business Overview
  76. 8.13.3 Endo Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Endo Transdermal Drug Delivery System Product Portfolio
  78. 8.13.5 Endo Recent Developments
  79. 8.14 Huarun 999
  80. 8.14.1 Huarun 999 Company Information
  81. 8.14.2 Huarun 999 Business Overview
  82. 8.14.3 Huarun 999 Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Huarun 999 Transdermal Drug Delivery System Product Portfolio
  84. 8.14.5 Huarun 999 Recent Developments
  85. 8.15 Haw Par
  86. 8.15.1 Haw Par Company Information
  87. 8.15.2 Haw Par Business Overview
  88. 8.15.3 Haw Par Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Haw Par Transdermal Drug Delivery System Product Portfolio
  90. 8.15.5 Haw Par Recent Developments
  91. 8.16 Nichiban
  92. 8.16.1 Nichiban Company Information
  93. 8.16.2 Nichiban Business Overview
  94. 8.16.3 Nichiban Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Nichiban Transdermal Drug Delivery System Product Portfolio
  96. 8.16.5 Nichiban Recent Developments
  97. 8.17 Mentholatum
  98. 8.17.1 Mentholatum Company Information
  99. 8.17.2 Mentholatum Business Overview
  100. 8.17.3 Mentholatum Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Mentholatum Transdermal Drug Delivery System Product Portfolio
  102. 8.17.5 Mentholatum Recent Developments
  103. 8.18 Laboratoires Genevrier
  104. 8.18.1 Laboratoires Genevrier Company Information
  105. 8.18.2 Laboratoires Genevrier Business Overview
  106. 8.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Laboratoires Genevrier Transdermal Drug Delivery System Product Portfolio
  108. 8.18.5 Laboratoires Genevrier Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst